Revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Celldex Therapeutics, Inc. (CLDX)
Price$39.26Cached quote
Net income
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $7.0M | $6.9M | $2.4M | $4.7M | $7.4M | $3.6M | $9.5M | $12.7M | $6.8M | $5.5M | $3.6M | $4.1M | $11.2M | $9.3M | $46.8M | $15.2M |
| Gross profit | $1.3M | $6.8M | $6.6M | $2.3M | $4.6M | $7.2M | $3.5M | $8.8M | $12.0M | $5.2M | — | — | — | — | — | — | — |
| Gross margin | 87.06% | 97.15% | 95.64% | 95.76% | 97.85% | 97.30% | 97.20% | 92.66% | 94.51% | 76.42% | — | — | — | — | — | — | — |
| Research & development | $245.1M | $163.6M | $118.0M | $82.3M | $53.3M | $42.5M | $42.7M | $66.4M | $96.2M | $102.7M | $100.2M | $104.4M | $67.4M | $47.4M | $32.4M | $27.6M | $26.2M |
| Operating expenses | $288.9M | $202.1M | $161.4M | $117.6M | $75.9M | $70.8M | $58.6M | $166.0M | $134.3M | $139.7M | $135.0M | $126.0M | $85.6M | $69.3M | $52.7M | $53.2M | $52.0M |
| Operating income | −$287.4M | −$195.1M | −$154.5M | −$115.2M | −$71.2M | −$63.4M | −$55.0M | −$156.4M | −$121.5M | −$132.9M | −$129.5M | −$122.4M | −$81.4M | −$58.1M | −$43.4M | −$6.5M | −$36.9M |
| Operating margin | −18,599.81% | −2,778.89% | −2,245.27% | −4,889.01% | −1,531.78% | −854.06% | −1,540.19% | −1,640.13% | −953.68% | −1,958.68% | −2,363.89% | −3,414.11% | −1,981.08% | −518.45% | −468.42% | −13.79% | −242.75% |
| EBITDA | −$284.0M | −$191.9M | −$151.5M | −$112.3M | −$68.2M | −$59.4M | −$50.2M | −$152.9M | −$117.1M | −$129.8M | −$126.5M | −$120.0M | −$79.5M | −$56.0M | −$41.2M | −$3.7M | −$34.3M |
| EBITDA margin | −18,381.04% | −2,733.63% | −2,201.57% | −4,766.14% | −1,465.81% | −801.09% | −1,404.23% | −1,602.63% | −919.04% | −1,913.07% | −2,309.18% | −3,347.52% | −1,934.08% | −500.18% | −444.16% | −7.99% | −225.74% |
| Net income | −$258.8M | −$157.9M | −$141.4M | −$112.3M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net profit margin | −16,748.03% | −2,248.76% | −2,054.76% | −4,765.59% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$3.90 | -$2.45 | -$2.92 | -$2.40 | -$1.64 | -$2.02 | -$3.51 | -$14.48 | -$10.86 | -$18.99 | -$293.28 | -$295.52 | -$228.36 | -$228.36 | -$252.99 | -$17.91 | -$411.94 |
| Diluted EPSper diluted share | -$3.90 | -$2.45 | -$2.92 | -$2.40 | -$1.64 | -$2.02 | -$3.51 | -$14.48 | -$10.86 | -$18.99 | -$293.28 | -$295.52 | -$228.36 | -$228.36 | -$252.99 | -$17.91 | -$411.94 |
Owners
Reported shareholders
12.16%of listed shares
WELLINGTON MANAGEMENT GROUP LLP9.54M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
WELLINGTON MANAGEMENT GROUP LLP | 12.16%9.54M shares |
BlackRock, Inc. | 8.92%7M shares |
Kynam Capital Management, LP | 6.78%5.32M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 5.97%4.69M shares |
STATE STREET CORP | 4.97%3.9M shares |
FMR LLC | 4.74%3.72M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.41%3.46M shares |
Deep Track Capital, LP | 3.74%2.94M shares |
Logos Global Management LP | 2.68%2.1M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.58%2.02M shares |
Eversept Partners, LP | 2.28%1.79M shares |
GOLDMAN SACHS GROUP INC | 2.06%1.62M shares |
Assenagon Asset Management S.A. | 2.01%1.58M shares |
Commodore Capital LP | 1.72%1.35M shares |
Bellevue Group AG | 1.53%1.2M shares |
BAKER BROS. ADVISORS LP | 1.51%1.18M shares |
MILLENNIUM MANAGEMENT LLC | 1.49%1.17M shares |
DIMENSIONAL FUND ADVISORS LP | 1.37%1.07M shares |
AMERICAN CENTURY COMPANIES INC | 1.33%1.04M shares |
EVENTIDE ASSET MANAGEMENT, LLC | 1.32%1.04M shares |
Percentages use 78.5M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 4, 2025Form 4 | Jimenez Freddy A.SVP & GENERAL COUNSEL | SellCommon Stock | 4.2K | $29.10 | $121.2K | 30.8K |
| Nov 13, 2025Form 4 | Wright Richard M.Other | SellCommon Stock | 49.3K | $24.00 | $1.18M | 20.8K |
| Aug 13, 2025Form 4 | Jimenez Freddy A.SVP & GENERAL COUNSEL | SellCommon Stock | 430 | $25.42 | $10.9K | 35.0K |
| Aug 13, 2025Form 4 | Jimenez Freddy A.SVP & GENERAL COUNSEL | SellCommon Stock | 341 | $23.95 | $8.2K | 35.4K |
| Nov 11, 2024Form 4 | Marucci Anthony SPRESIDENT & CEO | BuyCommon Stock | 11.5K | $26.82 | $308.4K | 40.3K |